[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 235
6. Dogan A, Ngu LS, Ng SH, Cervi PL: Pathology and clinical features of angioimmunoblastic T-cell lymphoma after successful treatment with thalidomide. Leukemia; 2005 May;19(5):873-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pathology and clinical features of angioimmunoblastic T-cell lymphoma after successful treatment with thalidomide.
  • [MeSH-major] Lymphoma, T-Cell / drug therapy. Lymphoma, T-Cell / pathology. Thalidomide / therapeutic use

  • Hazardous Substances Data Bank. THALIDOMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15744336.001).
  • [ISSN] 0887-6924
  • [Journal-full-title] Leukemia
  • [ISO-abbreviation] Leukemia
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, CD; 4Z8R6ORS6L / Thalidomide
  •  go-up   go-down


7. Niino D, Komohara Y, Murayama T, Aoki R, Kimura Y, Hashikawa K, Kiyasu J, Takeuchi M, Suefuji N, Sugita Y, Takeya M, Ohshima K: Ratio of M2 macrophage expression is closely associated with poor prognosis for Angioimmunoblastic T-cell lymphoma (AITL). Pathol Int; 2010 Apr;60(4):278-83
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ratio of M2 macrophage expression is closely associated with poor prognosis for Angioimmunoblastic T-cell lymphoma (AITL).
  • Angioimmunoblastic T-cell lymphoma (AITL) is a peripheral T-cell lymphoma characterized by systemic disease with polymorphous infiltrate including macrophages.
  • Although many studies of tumor-associated macrophage (TAM) populations in various malignant tumors have been published, only a few have dealt with activation of macrophage phenotypes such as M1 and M2 in tumor tissue.
  • [MeSH-major] Antigens, Differentiation, Myelomonocytic / immunology. Lymphoma, T-Cell, Peripheral / immunology. Lymphoma, T-Cell, Peripheral / mortality. Macrophages / immunology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Immunoblastic Lymphadenopathy / immunology. Immunoblastic Lymphadenopathy / pathology. Immunohistochemistry. Kaplan-Meier Estimate. Male. Middle Aged. Prognosis. Severity of Illness Index. Survival Analysis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20403029.001).
  • [ISSN] 1440-1827
  • [Journal-full-title] Pathology international
  • [ISO-abbreviation] Pathol. Int.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / Antigens, Differentiation, Myelomonocytic
  •  go-up   go-down


8. Coca Díaz F, García Alhambra Mde L, Rada Martínez S, Menárguez J, Serra Rexach JA: [Angioimmunoblastic lymphoma in a 73-year-old woman]. Rev Esp Geriatr Gerontol; 2008 Mar-Apr;43(2):117-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Angioimmunoblastic lymphoma in a 73-year-old woman].
  • [Transliterated title] Linfoma angioinmunoblástico en anciana de 73 años.
  • We describe the case of a 73-year-old woman with constitutional disorder and pain in the lower limbs, leading to initial suspicion of multiple myeloma.
  • After a fulminant clinical course for a few days, the patient died, and a postmortem diagnosis of angioimmunoblastic lymphoma was established.
  • We review the main aspects of this highly infrequent disease, the pathogenesis of which remains uncertain.
  • [MeSH-major] Immunoblastic Lymphadenopathy / diagnosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18682123.001).
  • [ISSN] 0211-139X
  • [Journal-full-title] Revista española de geriatría y gerontología
  • [ISO-abbreviation] Rev Esp Geriatr Gerontol
  • [Language] spa
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Spain
  •  go-up   go-down


9. Wang FX, Zhang XJ, Pan L, Qiao SK, Guo XL, Dong ZR: [Angioimmunoblastic T-cell lymphoma with autoimmune hemolytic anemia and pure red cell aplasia]. Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2007 Aug;15(4):862-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Angioimmunoblastic T-cell lymphoma with autoimmune hemolytic anemia and pure red cell aplasia].
  • Angioimmunoblastic T-cell lymphoma (AILT) is a peripheral T-cell lymphoma often complicated autoimmune phenomena such as autoimmune cytopenia, and is a truly rare type of NHL.
  • In order to investigate the clinical features, pathological manifestation of this lymphoma, and to explore its therapy protocol, a 37-years old patient with AILT was investigated.
  • The warm type autoimmune hemolytic anemia (AIHA) and pure red cell aplasia (PRCA) were co-existed.
  • In conclusion, the AITL patient complicated with AIHA and PRCA was successfully diagnosed, the lymphonode biopsy and bone marrow smear showed more significant, the chemotherapy protocol of CHOP-E can give some effect to cure such angioimmunoblastic T cell lymphoma.


10. Yamamoto H, Miwa H, Kato Y, Nakamura S, Hara K, Nitta M: Angioimmunoblastic T cell lymphoma with an unusual proliferation of Epstein-Barr virus-associated large B cells arising in a patient with progressive systemic sclerosis. Acta Haematol; 2005;114(2):108-12
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Angioimmunoblastic T cell lymphoma with an unusual proliferation of Epstein-Barr virus-associated large B cells arising in a patient with progressive systemic sclerosis.
  • We report an unusual case of angioimmunoblastic T cell lymphoma arising in the setting of 5 years of immunosuppressive treatment for progressive systemic sclerosis.
  • Southern blot study demonstrated the clonal rearrangement of T cell receptor beta-chain gene, but not of immunoglobulin heavy chain gene.
  • Phenotypical examination of the lymph node also revealed the predominance of CD4+ T cells in addition to the proliferation of follicular dendritic cells, but no light chain restriction in large B cell components.
  • Based on the combined data described here, our preferred diagnosis was angioimmunoblastic T cell lymphoma with Epstein-Barr virus-associated B cell lymphoproliferative disorder, the pathogenesis of which was suggested to be closely associated with immunosuppressive treatment for progressive systemic sclerosis.
  • [MeSH-major] Epstein-Barr Virus Infections / pathology. Herpesvirus 4, Human. Lymphoma, B-Cell / pathology. Lymphoma, T-Cell / pathology. Scleroderma, Diffuse / pathology

  • Genetic Alliance. consumer health - Diffuse Scleroderma.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2005 S. Karger AG, Basel.
  • (PMID = 16103635.001).
  • [ISSN] 0001-5792
  • [Journal-full-title] Acta haematologica
  • [ISO-abbreviation] Acta Haematol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Switzerland
  •  go-up   go-down


11. Tang XF, Li GD, Li YL, Liang DN, Xia T, Zhou JY, Yao YQ, Wu WQ, Wang ZG, Yang YH, Tang XB, Bai YQ, Ding Q: [Expressions of CXCL13, CD10 and bcl-6 in angioimmunoblastic T-cell lymphoma and peripheral T-cell lymphoma, not otherwise specified]. Zhonghua Bing Li Xue Za Zhi; 2009 Apr;38(4):224-30
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Expressions of CXCL13, CD10 and bcl-6 in angioimmunoblastic T-cell lymphoma and peripheral T-cell lymphoma, not otherwise specified].
  • OBJECTIVE: To study the value of immunomarkers CXCL13, CD10, bcl-6 in pathologic diagnosis of angioimmunoblastic T-cell lymphoma (AITL).
  • METHODS: One hundred and fifteen cases of AITL, 30 cases of peripheral T-cell lymphoma, not otherwise specified (PTCL, NOS) and 30 cases of reactive lymph nodes with paracortical hyperplasia (RH) encountered during the period from January, 1990 to January, 2008 were retrieved from the archival files of the Department of Pathology, West China Hospital of Sichuan University, China.
  • The morphologic features were reviewed and compared.
  • RESULTS: Regressed follicles were evident in 7.8% (9/115) of AITL cases, 6.7% (2/30) of PTCL, NOS cases and 83.3% (25/30) of RH cases, respectively.
  • A marked increase of number of arborizing venules was shown in 98.3% (113/115) of AITL cases, 63.3% (19/30) of PTCL, NOS cases and 76.7% (23/30) of RH cases, respectively.
  • In AITL, 96.5% (111/115) of cases showed CXCL13 expression, in contrast to 26.7% (8/30) of PTCL, NOS.
  • Expression of CD10 and bcl-6 were found in the neoplastic cells in 50.4% (58/115) and 78.3% (90/115) of AITL, and 3.3% (1/30) and 3.3% (1/30) of PTCL, NOS, respectively.
  • CONCLUSIONS: AITL is a type of lymphoma originated from the follicular helper T cells.
  • Detailed morphologic assessment and use of immunohistochemical markers are essential for accurate diagnosis.
  • [MeSH-major] Chemokine CXCL13 / metabolism. Immunoblastic Lymphadenopathy / pathology. Lymphoma, T-Cell, Peripheral / pathology. Neprilysin / metabolism. Proto-Oncogene Proteins c-bcl-6 / metabolism
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Diagnosis, Differential. Female. Gene Rearrangement, gamma-Chain T-Cell Antigen Receptor. Humans. Lymph Nodes / metabolism. Lymph Nodes / pathology. Male. Middle Aged. Pseudolymphoma / metabolism. Pseudolymphoma / pathology

  • Genetic Alliance. consumer health - Peripheral T-cell lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19575892.001).
  • [ISSN] 0529-5807
  • [Journal-full-title] Zhonghua bing li xue za zhi = Chinese journal of pathology
  • [ISO-abbreviation] Zhonghua Bing Li Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / CXCL13 protein, human; 0 / Chemokine CXCL13; 0 / Proto-Oncogene Proteins c-bcl-6; EC 3.4.24.11 / Neprilysin
  •  go-up   go-down


12. Chang ST, Lu CL, Chuang SS: CD52 expression in non-mycotic T- and NK/T-cell lymphomas. Leuk Lymphoma; 2007 Jan;48(1):117-21
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] CD52 expression in non-mycotic T- and NK/T-cell lymphomas.
  • Campath-1H or alemtuzumab, a human anti-CD52, has been shown to be effective in T-cell malignancies; however, there is very limited information on CD52 expression in T-cell lymphoma (TCL).
  • Fourteen cases of angioimmunoblastic T-cell lymphoma (AITL) were excluded as there were no reliable criteria to differentiate whether the CD52-positive cells were neoplastic T-cells, which are usually small-sized, or the usually abundant, small-to-large residual/reactive B-cells in this lymphoma sub-type.
  • In the remaining 83 tumors, CD52 was expressed in 29 (35%) tumors including 8/17 (47%) NK/T-cell lymphomas, 14/35 (40%) unspecified peripheral TCLs and 4/18 (22%) anaplastic large cell lymphomas.
  • [MeSH-major] Antigens, CD / metabolism. Antigens, Neoplasm / metabolism. Glycoproteins / metabolism. Lymphoma, T-Cell / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17325855.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Antigens, Neoplasm; 0 / CD52 antigen; 0 / Glycoproteins
  •  go-up   go-down


13. Rodríguez J, Conde E, Gutiérrez A, Arranz R, Gandarillas M, Leon A, Ojanguren J, Sureda A, Carrera D, Bendandi M, Moraleda J, Ribera JM, Albo C, Morales A, García JC, Fernández P, Cañigral G, Bergua J, Caballero MD, Grupo Español de Linfomas/Trasplante Autólogo de Médula Osea: Prolonged survival of patients with angioimmunoblastic T-cell lymphoma after high-dose chemotherapy and autologous stem cell transplantation: the GELTAMO experience. Eur J Haematol; 2007 Apr;78(4):290-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prolonged survival of patients with angioimmunoblastic T-cell lymphoma after high-dose chemotherapy and autologous stem cell transplantation: the GELTAMO experience.
  • OBJECTIVES: Angioimmunoblastic T-cell lymphoma (AIL) is a rare lymphoma with a poor prognosis and no standard treatment.
  • Here, we report our experiences with 19 patients treated with high-dose chemotherapy and autologous stem cell transplantation (HDC/ASCT) within the GELTAMO co-operative group between 1992 and 2004.
  • Most patients received peripheral stem cells (90%) coupled with BEAM or BEAC as conditioning regimen (79%).
  • After a median follow-up of 25 months, eight patients died (seven of progressive disease and secondary neoplasia), while actuarial overall survival and progression-free survival at 3 yr was 60% and 55%.
  • Prognostic factors associated with a poor outcome included bone marrow involvement, transplantation in refractory disease state, attributing more than one factor of the age-adjusted-International Prognostic Index, Pretransplant peripheral T-cell lymphoma (PTCL) Score or Prognostic Index for PTCL.
  • CONCLUSIONS: More than half of the patients with AIL that display unfavourable prognostic factors at diagnosis or relapse would be expected to be alive and disease-free after 3 yr when treated with HDC/ASCT.
  • Patients who are transplanted in a refractory disease state do not benefit from this procedure.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Hematopoietic Stem Cell Transplantation. Immunoblastic Lymphadenopathy / therapy. Lymphoma, T-Cell, Peripheral / therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Combined Modality Therapy. Disease Progression. Disease-Free Survival. Dose-Response Relationship, Drug. Female. Follow-Up Studies. Humans. Male. Middle Aged. Prognosis. Registries. Severity of Illness Index. Spain. Survival Rate. Transplantation, Autologous. Treatment Outcome

  • Genetic Alliance. consumer health - Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17378891.001).
  • [ISSN] 0902-4441
  • [Journal-full-title] European journal of haematology
  • [ISO-abbreviation] Eur. J. Haematol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Denmark
  •  go-up   go-down


1
Advertisement
4. Li BZ, Zhou XY, Ye HT, Yang WT, Fan YZ, Lu HF, Shi DR: [Abnormal expression of bcl-10 protein in extranodal marginal zone B cell lymphoma of mucosa-associated lymphoid tissue lymphoma type]. Zhonghua Bing Li Xue Za Zhi; 2007 Dec;36(12):819-24
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Abnormal expression of bcl-10 protein in extranodal marginal zone B cell lymphoma of mucosa-associated lymphoid tissue lymphoma type].
  • OBJECTIVE: To evaluate the diagnostic role of nuclear expression of bcl-10 protein in extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue (MALT) type.
  • METHODS: One hundred and forty cases of MALT lymphoma were collected from Cancer Hospital of Fudan University (including 38 cases from stomach, 35 cases from ocular adnexa, 16 cases from intestine, 15 cases from skin, 15 cases from salivary gland, 14 cases from lung, 3 cases from thyroid and 4 cases from other sites).
  • Ten cases of reactive follicular hyperplasia of tonsil, 5 cases of reactive lymphoid hyperplasia of orbit and 143 cases of non-Hodgkin's lymphoma other than MALT lymphoma (including 20 cases of NK/T cell lymphoma, 20 cases of follicular lymphomas, 20 cases of anaplastic large cell lymphomas, 20 cases of nodal diffuse large cell B-cell lymphoma (DLBCL), 10 cases of gastric diffuse large B-cell lymphoma, 13 cases of nodal marginal zone B-cell lymphoma, 12 cases of mantle cell lymphoma, 11 cases of splenic marginal zone B-cell lymphoma, 6 cases of angioimmunoblastic T-cell lymphoma, 6 cases of peripheral T-cell lymphoma, not otherwise specified, 3 cases of small lymphocytic lymphoma, 1 case of lymphoplasmacytic lymphoma and 1 case of plasmacytoma were used as controls.
  • As for non-MALT lymphomas, 3 gastric DLBCL showed nuclear expression.
  • In some cases of lymphoma, bcl-10 was expressed in tumor cells but not in reactive lymphoid cells.
  • On the other hand, 92.1% (129/140) of MALT lymphoma were bcl-10 positive.
  • The staining was most intense in MALT lymphoma of ocular adnexa.
  • Cytoplasmic expression of bcl-10 is seen in many different kinds of non-Hodgkin's lymphoma and reactive lymphoid conditions.
  • In some cases of lymphoma, bcl-10 is expressed in tumor cells but not in reactive lymphoid cells, suggesting a possible role of abnormal bcl-10 expression in tumorgenesis.
  • Nuclear expression of bcl-10 is seen mainly in MALT lymphoma, especially when occurring in ocular adnexa and lung.
  • [MeSH-major] Adaptor Proteins, Signal Transducing / genetics. Gene Expression Regulation, Neoplastic. Lymphoma, B-Cell, Marginal Zone / genetics. Lymphoma, B-Cell, Marginal Zone / pathology
  • [MeSH-minor] Antigens, CD20 / immunology. Cell Nucleus / genetics. Cytoplasm / genetics. Humans. Lymphocytes / pathology. Palatine Tonsil / pathology. Pseudolymphoma / genetics

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18346354.001).
  • [ISSN] 0529-5807
  • [Journal-full-title] Zhonghua bing li xue za zhi = Chinese journal of pathology
  • [ISO-abbreviation] Zhonghua Bing Li Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Adaptor Proteins, Signal Transducing; 0 / Antigens, CD20; 0 / BCL10 protein, human
  •  go-up   go-down


15. Saito M, Fukuda T, Shiohara T, Homori M: Angioimmunoblastic T-cell lymphoma: a relatively common type of T-cell lymphoma in Sjögren's syndrome. Clin Exp Rheumatol; 2005 Nov-Dec;23(6):888-90
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Angioimmunoblastic T-cell lymphoma: a relatively common type of T-cell lymphoma in Sjögren's syndrome.
  • An increased risk of developing lymphoma has been indicated in Sjögren's syndrome (SS), and the lymphomas in SS are usually B-cell type in origin.
  • Interestingly, despite the rather low frequency of T-cell lymphoma in SS, angioimmunoblastic T-cell lymphoma (AILD) constitute the majority of T-cell lymphomas associated with SS.
  • To the best of our knowledge, including our case, at least 11 out of 23 (48%) cases of T-cell lymphoma reported in association with SS, were AILD.
  • The fact that the development of B-cell lymphoma in SS is much more frequent than that of T-cell lymphoma, might be explained by differences in the situation between B and T cells, although the exact mechanism still remains uncertain.
  • [MeSH-major] Immunoblastic Lymphadenopathy / complications. Lymphoma, T-Cell / complications. Sjogren's Syndrome / complications

  • MedlinePlus Health Information. consumer health - Sjogren's Syndrome.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16396711.001).
  • [ISSN] 0392-856X
  • [Journal-full-title] Clinical and experimental rheumatology
  • [ISO-abbreviation] Clin. Exp. Rheumatol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


16. Miyazaki K, Masuya M, Yamaguchi M, Isaka S, Nakase K, Kobayashi T, Nakamura S, Shiku H: [Angioimmunoblastic T-cell lymphoma occurring four months after autologous peripheral blood stem cell transplantation with high-dose chemotherapy for follicular lymphoma]. Rinsho Ketsueki; 2005 Sep;46(9):1065-70
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Angioimmunoblastic T-cell lymphoma occurring four months after autologous peripheral blood stem cell transplantation with high-dose chemotherapy for follicular lymphoma].
  • A 62-year-old Japanese woman was diagnosed as having follicular lymphoma (FL, grade 3, CS IIIA, IPI high-intermediate risk) in May 1998.
  • High-dose etoposide was used for autologous peripheral stem cell mobilization.
  • In May 1999, she underwent high-dose chemotherapy with autologous peripheral blood stem cell transplantation (auto-PBSCT).
  • Four months after the auto-PBSCT, bilateral cervical lymphadenopathy developed.
  • Histopathological findings from a biopsied cervical lymph node showed angioimmunoblastic T-cell lymphoma (AILT).
  • The patient was treated with modified CVP therapy, and she is alive with no evidence of lymphoma five years after auto-PBSCT.
  • Clinical and histopathological findings showed that the FL and AILT in this case were not concomitant.
  • It is thought that in this case, the AILT developed as a post-transplant lymphoproliferative disorder after auto-PBSCT for the FL.
  • [MeSH-major] Antineoplastic Agents, Phytogenic / adverse effects. Etoposide / adverse effects. Immunoblastic Lymphadenopathy / etiology. Lymphoma, Follicular / therapy. Lymphoma, T-Cell / etiology. Peripheral Blood Stem Cell Transplantation / adverse effects


17. Konstantinou K, Yamamoto K, Ishibashi F, Mizoguchi Y, Kurata M, Nakagawa Y, Suzuki K, Sawabe M, Ohta M, Miyakoshi S, Crawley JT, Kitagawa M: Angiogenic mediators of the angiopoietin system are highly expressed by CD10-positive lymphoma cells in angioimmunoblastic T-cell lymphoma. Br J Haematol; 2009 Mar;144(5):696-704
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Angiogenic mediators of the angiopoietin system are highly expressed by CD10-positive lymphoma cells in angioimmunoblastic T-cell lymphoma.
  • Angioimmunoblastic T-cell lymphoma (AILT) is a malignant disease of peripheral T-cell origin that is characterized by a prominent proliferation of high endothelial venules in the lymph node.
  • To investigate angiogenic mechanisms in AILT we measured the angiogenic mediator gene expression levels in the lymph nodes of 54 non-Hodgkin lymphoma patients, by immunostaining and quantitative reverse transcription polymerase chain reaction.
  • Angiogenic mediators angiopoietin (Ang) 1 (ANGPT1), Ang2 (ANGPT2) and their receptor, Tie2 (TEK), vascular endothelial growth factor (VEGF; VEGFA) and its receptor, VEGFR2 (KDR), and hepatocyte growth factor (HGF) and its receptor, c-Met (MET) were all more highly expressed in AILT lymph nodes (16 cases) than in B-cell lymphomas (24 cases).
  • Moreover, significantly higher Ang1 and Tie2 expression was detected in AILT cases with CD10-positive neoplastic T-cells by comparison with unspecified peripheral T-cell lymphoma (14 cases).
  • These results suggest that the angiopoietin system may play an important role in the development of high vascularity in AILT lymph nodes.
  • Consequently, as neoplastic T-cells and follicular dendritic cells are both increased in AILT and may represent an important source of angiogenic mediators, targeting these cells with anti-angiogenic strategies might represent a novel therapy for AILT.
  • [MeSH-major] Angiopoietins / metabolism. Lymph Nodes / metabolism. Lymphoma, T-Cell, Peripheral / metabolism

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19120365.001).
  • [ISSN] 1365-2141
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Angiopoietin-1; 0 / Angiopoietin-2; 0 / Angiopoietins; 0 / Antigens, CD3; 0 / Biomarkers, Tumor; 0 / Receptors, Complement 3d; 0 / Vascular Endothelial Growth Factor A; EC 2.7.10.1 / Receptor, TIE-2; EC 3.4.24.11 / Neprilysin
  •  go-up   go-down


18. Imafuku S, Yoshimura D, Moroi Y, Urabe K, Furue M: Systemic varicella zoster virus reinfection in a case of angioimmunoblastic T-cell lymphoma. J Dermatol; 2007 Jun;34(6):387-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Systemic varicella zoster virus reinfection in a case of angioimmunoblastic T-cell lymphoma.
  • Angioimmunoblastic T-cell lymphoma (AITL) is a rare subtype of peripheral T-cell lymphoma that causes immunological disorders such as immunosuppression, autoimmune disease-like symptoms and allergy.
  • [MeSH-major] Chickenpox / diagnosis. Lymphoma, T-Cell / diagnosis
  • [MeSH-minor] Acyclovir / administration & dosage. Aged. Antineoplastic Combined Chemotherapy Protocols / adverse effects. Antiviral Agents / administration & dosage. Cyclophosphamide / administration & dosage. Diagnosis, Differential. Doxorubicin / administration & dosage. Doxorubicin / analogs & derivatives. Herpesvirus 3, Human / immunology. Humans. Immunocompromised Host. Infusions, Intravenous. Male. Prednisone / administration & dosage. Recurrence. Vincristine / administration & dosage

  • MedlinePlus Health Information. consumer health - Chickenpox.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • Hazardous Substances Data Bank. ACYCLOVIR .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17535405.001).
  • [ISSN] 0385-2407
  • [Journal-full-title] The Journal of dermatology
  • [ISO-abbreviation] J. Dermatol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antiviral Agents; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; D58G680W0G / pirarubicin; VB0R961HZT / Prednisone; X4HES1O11F / Acyclovir
  •  go-up   go-down


19. Noorali S, Nasir MI, Pervez S: Characterization of angioimmunoblastic T-cell lymphomas (AILT) and its association with Epstein-Barr virus (EBV) in Pakistani patients. J Coll Physicians Surg Pak; 2005 Jul;15(7):404-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Characterization of angioimmunoblastic T-cell lymphomas (AILT) and its association with Epstein-Barr virus (EBV) in Pakistani patients.
  • OBJECTIVE: To characterize angioimmunoblastic T-cell lymphoma (AILT) on morphological, immunohistochemical and molecular grounds and its association with Epstein-Barr virus (EBV) in Pakistani patients.
  • PATIENTS AND METHODS: Over a period of 11 years archival biopsy material of 13 AILT cases (lymph nodes), identified on the basis of histological and immunohistochemical criteria, using REAL and WHO classifications, were retrieved from the files of Department of Pathology.
  • Immunophenotyping was carried out by using CD45 (LCA), two T-cell markers CD45RO (UCHL1; monoclonal) and CD3 (polyclonal).
  • Polymerase chain reaction (PCR) was used to assess T-cell clonality for T-cell receptor (TCR)-b, g and immunoglobulin heavy chain (IgH) for FR2 and FR3 regions using primers recognizing conserved sequences of the variable (V), diversity (D) and joining (J) region segments.
  • Association of EBV in AILT cases was studied by PCR and in situ hybridization (ISH).
  • RESULTS: This study showed AILT to constitute 0.71% of all NHLs (non-Hodgkin's lymphoma) [both T and B].
  • All the 13 cases were largely negative for CD20 (L26), a B-cell marker, except few large scattered cells labelling.
  • PCR technique demonstrated clonal gene rearrangement of the TCR-b, g and IgH regions in 3 (23.1%), 7 (53.8%) and 3 (23.1%) AILT cases, respectively out of 13 cases.
  • Association of EBV was seen in 11 out of 13 cases (84.6%) of AILT by PCR.
  • CONCLUSION: The prevalence of AILT in the Pakistani population is slightly lower compared to other studies and that EBV is an etiological agent in pathogenesis of this disease.
  • [MeSH-major] Lymphoma, T-Cell / virology

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16197868.001).
  • [ISSN] 1022-386X
  • [Journal-full-title] Journal of the College of Physicians and Surgeons--Pakistan : JCPSP
  • [ISO-abbreviation] J Coll Physicians Surg Pak
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Pakistan
  •  go-up   go-down


20. Kalyan K, Basu D, Soundararaghavan J: Immunohistochemical typing of non-Hodgkin's lymphoma-comparing working formulation and WHO classification. Indian J Pathol Microbiol; 2006 Apr;49(2):203-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immunohistochemical typing of non-Hodgkin's lymphoma-comparing working formulation and WHO classification.
  • The recent WHO classification of non-Hodgkin's lymphoma is based on the morphology and immunohistochemical expression of the lymphoma cells and to a lesser extent, on the molecular and cytogenetic findings.
  • Fifty-three cases of non-Hodgkin's lymphoma were included in the study.
  • Of these, seven cases were primary extra nodal lymphomas.
  • Twenty two patients had peripheral blood and/or bone marrow involvement.
  • The two most common types encountered were diffuse large cell lymphoma and small lymphocytic lymphoma.
  • 38 cases (72%) showed B cell expression and 12 cases (22.5%) showed T cell expression.
  • B-cell diffuse large cell lymphoma (26%) was found to be the predominant B cell non-Hodgkin's lymphoma.
  • The commonest T-cell lymphoma was T lymphoblastic lymphoma (67%) followed by peripheral T cell angioimmunoblastic lymphoma (25%).
  • Immunohistochemistry is a useful and necessary diagnostic modality and helps subdivide prognostically different types of non-Hodgkin's lymphoma.
  • [MeSH-major] Lymphoma, Non-Hodgkin / classification

  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16933715.001).
  • [ISSN] 0377-4929
  • [Journal-full-title] Indian journal of pathology & microbiology
  • [ISO-abbreviation] Indian J Pathol Microbiol
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] India
  • [Chemical-registry-number] 0 / Antigens, CD20; 0 / Antigens, CD3
  •  go-up   go-down


81. Sekine R, Ohno N, Uchimura K, Oyaizu N, Tojo A: [Severe systemic edema correlated with serum VEGF titer in a patient with angioimmunoblastic T-cell lymphoma]. Rinsho Ketsueki; 2007 Nov;48(11):1498-502
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Severe systemic edema correlated with serum VEGF titer in a patient with angioimmunoblastic T-cell lymphoma].
  • A 73-year-old woman was admitted with generalized lymphadenopathy, marked protrusion of the abdomen, severe systemic edema, oliguria, and dyspnea.
  • Histological examination of a cervical lymph node specimen showed a typical structure of angioimmunoblastic T-cell lymphoma.
  • CT scan revealed whole paraaortic lymphadenopathy, marked edematous lesions in the subcutaneous tissues and mesenterium, but small amounts of pleural effusion and ascites.
  • [MeSH-major] Edema / etiology. Immunoblastic Lymphadenopathy / blood. Immunoblastic Lymphadenopathy / complications. Lymphoma, T-Cell, Peripheral / blood. Lymphoma, T-Cell, Peripheral / complications. Vascular Endothelial Growth Factors / blood

  • Genetic Alliance. consumer health - Edema.
  • MedlinePlus Health Information. consumer health - Edema.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18080509.001).
  • [ISSN] 0485-1439
  • [Journal-full-title] [Rinshō ketsueki] The Japanese journal of clinical hematology
  • [ISO-abbreviation] Rinsho Ketsueki
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Vascular Endothelial Growth Factors
  •  go-up   go-down


82. Wang XQ, Sino-US Leukemia Cooperative Group of Shanghai: [Cytogenetic study on 155 cases of non-Hodgkin' s lymphoma]. Zhonghua Xue Ye Xue Za Zhi; 2006 Oct;27(10):656-60
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Cytogenetic study on 155 cases of non-Hodgkin' s lymphoma].
  • OBJECTIVE: To investigate the relationship between histopathological subtype of non-Hodgkin' s lymphoma(NHL) and chromosomal abnormalities, and compare the difference of chromosomal abnormalities between China and the West.
  • RESULTS: Diffuse large B-cell lymphoma( DLBCL) constituted 38.1% of the cases followed by follicular lymphoma(FL) 17.4% , small lymphocytic lymphoma( SLL) 10.3% , peripheral T-cell lymphoma ( PTCL) ( unspecified) 8.4%, and angioimmunoblastic lymphoma 7.1%.
  • The incidence of chromosomal abnormalities among FL, SLL, DLBCL, anaplastic large cell lymphoma (ALCL) and precursor T-cell lymphoblastic lymphoma (TLBL) was 96.3% , 87.5% , 86.4%, 83.3% and 83.3%, respectively.
  • Normal karyotype was observed in 8/11 cases with angioimmunoblastic T-cell lymphoma patients.
  • The incidence of chromosomal abnormalities in angioimmunoblastic T-cell lymphoma was lower than that in the West.
  • [MeSH-major] Lymphoma, Non-Hodgkin / genetics. Lymphoma, Non-Hodgkin / pathology
  • [MeSH-minor] Adult. Chromosome Structures. Cytogenetic Analysis. Female. Humans. In Situ Hybridization, Fluorescence. Lymphoma, Large B-Cell, Diffuse / classification. Lymphoma, Large B-Cell, Diffuse / genetics. Lymphoma, Large B-Cell, Diffuse / pathology. Male

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • Genetic Alliance. consumer health - Non-Hodgkin Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17343195.001).
  • [ISSN] 0253-2727
  • [Journal-full-title] Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi
  • [ISO-abbreviation] Zhonghua Xue Ye Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


83. Kambouchner M, Bernaudin JF: Intralobular pulmonary lymphatic distribution in normal human lung using D2-40 antipodoplanin immunostaining. J Histochem Cytochem; 2009 Jul;57(7):643-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intralobular pulmonary lymphatic distribution in normal human lung using D2-40 antipodoplanin immunostaining.
  • This thin intralobular lymphatic network may play a key pathophysiological role in a wide variety of alveolar and interstitial lung diseases and requires further investigation.
  • [MeSH-major] Antibodies, Monoclonal. Lung / anatomy & histology. Lymphatic Vessels / anatomy & histology. Membrane Glycoproteins / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Adv Drug Deliv Rev. 2001 Aug 23;50(1-2):3-20 [11489331.001]
  • [Cites] J Histochem Cytochem. 2008 Dec;56(12):1087-92 [18765840.001]
  • [Cites] Pathol Annu. 1971;6:365-415 [4949370.001]
  • [Cites] Experientia. 1976 Jan 15;32(1):1-12 [765142.001]
  • [Cites] Lymphology. 1979 Sep;12(3):118-24 [542016.001]
  • [Cites] Environ Health Perspect. 1980 Apr;35:55-75 [6157524.001]
  • [Cites] Anat Rec. 1992 Aug;233(4):547-54 [1626714.001]
  • [Cites] Lymphology. 1993 Mar;26(1):42-8 [8464226.001]
  • [Cites] Anat Rec. 1994 Mar;238(3):368-73 [8179218.001]
  • [Cites] Am J Pathol. 1997 Oct;151(4):1141-52 [9327748.001]
  • [Cites] Am J Pathol. 2005 Mar;166(3):913-21 [15743802.001]
  • [Cites] Mod Pathol. 2005 Nov;18(11):1490-7 [15990898.001]
  • [Cites] Clin Cancer Res. 2005 Nov 1;11(21):7637-42 [16278382.001]
  • [Cites] Am J Pathol. 2006 Mar;168(3):1045-53 [16507917.001]
  • [Cites] J Histochem Cytochem. 2006 Apr;54(4):385-95 [16234507.001]
  • [Cites] Infect Immun. 2006 Sep;74(9):5397-401 [16926435.001]
  • [Cites] Int J Oncol. 2007 Sep;31(3):501-8 [17671675.001]
  • [Cites] Hum Pathol. 2008 Jan;39(1):49-55 [17904616.001]
  • [Cites] Curr Opin Crit Care. 2008 Feb;14(1):31-6 [18195623.001]
  • [Cites] Ann N Y Acad Sci. 2008;1131:1-12 [18519955.001]
  • [Cites] Hum Pathol. 2008 Aug;39(8):1234-8 [18602671.001]
  • [Cites] J Cutan Pathol. 2008 Oct;35(10):926-30 [18537863.001]
  • [Cites] Mod Pathol. 2002 Apr;15(4):434-40 [11950918.001]
  • (PMID = 19289553.001).
  • [ISSN] 0022-1554
  • [Journal-full-title] The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society
  • [ISO-abbreviation] J. Histochem. Cytochem.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Antigens, CD34; 0 / Membrane Glycoproteins; 0 / PDPN protein, human; 0 / monoclonal antibody D2-40
  • [Other-IDs] NLM/ PMC2699320
  •  go-up   go-down


84. Tripodo C, Gri G, Piccaluga PP, Frossi B, Guarnotta C, Piconese S, Franco G, Vetri V, Pucillo CE, Florena AM, Colombo MP, Pileri SA: Mast cells and Th17 cells contribute to the lymphoma-associated pro-inflammatory microenvironment of angioimmunoblastic T-cell lymphoma. Am J Pathol; 2010 Aug;177(2):792-802
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mast cells and Th17 cells contribute to the lymphoma-associated pro-inflammatory microenvironment of angioimmunoblastic T-cell lymphoma.
  • Reports focusing on the immunological microenvironment of peripheral T-cell lymphomas (PTCL) are rare.
  • Here we studied the reciprocal contribution of regulatory (Treg) and interleukin-17-producing (Th17) T-cells to the composition of the lymphoma-associated microenvironment of angioimmunoblastic T-cell lymphoma (AITL) and PTCL not otherwise specified on tissue microarrays from 30 PTCLs not otherwise specified and 37 AITLs.
  • We found that Th17 but not Treg cells were differently represented in the two lymphomas and correlated with the amount of mast cells (MCs) and granulocytes, which preferentially occurred in the cellular milieu of AITL cases.
  • [MeSH-major] Immunoblastic Lymphadenopathy / immunology. Inflammation / immunology. Lymphoma, T-Cell / immunology. Mast Cells / immunology. Th17 Cells / immunology. Tumor Microenvironment

  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • antibodies-online. View related products from antibodies-online.com (subscription/membership/fee required).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Curr Opin Immunol. 2007 Apr;19(2):217-23 [17306521.001]
  • [Cites] J Clin Invest. 2007 Mar;117(3):823-34 [17304354.001]
  • [Cites] Cancer Res. 2007 Nov 15;67(22):10703-10 [18006812.001]
  • [Cites] Annu Rev Immunol. 2008;26:705-39 [18370925.001]
  • [Cites] Blood. 2008 May 1;111(9):4463-70 [18292286.001]
  • [Cites] Nat Rev Immunol. 2008 Jun;8(6):478-86 [18483499.001]
  • [Cites] J Clin Oncol. 2008 Sep 1;26(25):4124-30 [18626005.001]
  • [Cites] Am J Clin Pathol. 2008 Oct;130(4):613-9 [18794055.001]
  • [Cites] Nat Immunol. 2008 Nov;9(11):1215-23 [18936782.001]
  • [Cites] J Clin Pathol. 2008 Nov;61(11):1160-7 [18755717.001]
  • [Cites] Crit Rev Oncol Hematol. 2008 Dec;68(3):264-71 [18684638.001]
  • [Cites] Immunity. 2008 Nov 14;29(5):771-81 [18993084.001]
  • [Cites] N Engl J Med. 2008 Nov 27;359(22):2313-23 [19038878.001]
  • [Cites] Hematology Am Soc Hematol Educ Program. 2008;:272-9 [19074096.001]
  • [Cites] Mucosal Immunol. 2008 Nov;1 Suppl 1:S43-6 [19079228.001]
  • [Cites] Oncologist. 2008 Dec;13(12):1246-54 [19056856.001]
  • [Cites] Haematologica. 2009 Jan;94(1):127-30 [19029148.001]
  • [Cites] Immunity. 2009 Jan 16;30(1):92-107 [19119024.001]
  • [Cites] Immunity. 2009 Mar 20;30(3):324-35 [19303387.001]
  • [Cites] Nat Rev Cancer. 2009 Apr;9(4):239-52 [19279573.001]
  • [Cites] Nat Rev Rheumatol. 2009 Jun;5(6):325-31 [19434074.001]
  • [Cites] Curr Opin Immunol. 2009 Jun;21(3):274-80 [19524429.001]
  • [Cites] Am J Hematol. 2009 Jul;84(7):435-8 [19484731.001]
  • [Cites] Cancer Res. 2009 Jul 15;69(14):5619-22 [19567669.001]
  • [Cites] Blood. 2009 Aug 6;114(6):1141-9 [19470694.001]
  • [Cites] Immunobiology. 2009;214(9-10):835-42 [19628296.001]
  • [Cites] Nat Rev Cancer. 2009 Sep;9(9):665-74 [19693095.001]
  • [Cites] N Engl J Med. 2009 Aug 27;361(9):888-98 [19710487.001]
  • [Cites] J Clin Oncol. 2009 Sep 1;27(25):4197-203 [19636021.001]
  • [Cites] J Immunol. 2009 Oct 1;183(7):4169-75 [19767566.001]
  • [Cites] Blood. 2009 Sep 24;114(13):2639-48 [19643985.001]
  • [Cites] Blood. 2009 Oct 1;114(14):2936-44 [19671921.001]
  • [Cites] Crit Rev Oncol Hematol. 2009 Nov;72(2):125-43 [19233683.001]
  • [Cites] Hum Pathol. 2010 Jan;41(1):79-87 [19740519.001]
  • [Cites] Blood. 2010 Feb 4;115(5):1026-36 [19965671.001]
  • [Cites] Trends Immunol. 2010 Mar;31(3):97-102 [20149743.001]
  • [Cites] Blood. 2010 Apr 8;115(14):2810-7 [20101023.001]
  • [Cites] Br J Haematol. 2010 Mar;148(5):673-89 [19961485.001]
  • [Cites] J Rheumatol. 2000 Apr;27(4):1087-90 [10782842.001]
  • [Cites] J Pathol. 2003 Feb;199(2):201-7 [12533833.001]
  • [Cites] J Immunol. 2003 Mar 15;170(6):3037-45 [12626558.001]
  • [Cites] Leuk Res. 2003 Aug;27(8):677-82 [12801524.001]
  • [Cites] Lab Invest. 2004 Nov;84(11):1512-9 [15311211.001]
  • [Cites] Leukemia. 1996 Sep;10(9):1504-8 [8751470.001]
  • [Cites] Acta Haematol. 2005;114(2):108-12 [16103635.001]
  • [Cites] Nat Rev Immunol. 2006 Apr;6(4):295-307 [16557261.001]
  • [Cites] Blood. 2007 Jun 1;109(11):4952-63 [17284527.001]
  • (PMID = 20595635.001).
  • [ISSN] 1525-2191
  • [Journal-full-title] The American journal of pathology
  • [ISO-abbreviation] Am. J. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Chemokine CXCL13; 0 / Cytokines; 0 / FOXP3 protein, human; 0 / Forkhead Transcription Factors; 0 / Interleukin-17; 0 / Interleukin-6
  • [Other-IDs] NLM/ PMC2913370
  •  go-up   go-down


85. Notas G, Xylouri I, Kritikos H, Stavroulaki E, Roditakis G, Boumpas D: A rare case of angioimmunoblastic T-cell lymphoma presenting with fever and late polyarthritis. Rheumatology (Oxford); 2009 Jul;48(7):859-60
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A rare case of angioimmunoblastic T-cell lymphoma presenting with fever and late polyarthritis.
  • [MeSH-major] Lymphoma, T-Cell / diagnosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19435859.001).
  • [ISSN] 1462-0332
  • [Journal-full-title] Rheumatology (Oxford, England)
  • [ISO-abbreviation] Rheumatology (Oxford)
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] England
  •  go-up   go-down


86. d'Amore F, Radford J, Relander T, Jerkeman M, Tilly H, Osterborg A, Morschhauser F, Gramatzki M, Dreyling M, Bang B, Hagberg H: Phase II trial of zanolimumab (HuMax-CD4) in relapsed or refractory non-cutaneous peripheral T cell lymphoma. Br J Haematol; 2010 Sep;150(5):565-73
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II trial of zanolimumab (HuMax-CD4) in relapsed or refractory non-cutaneous peripheral T cell lymphoma.
  • The efficacy and safety of zanolimumab (HuMax-CD4) in patients with relapsed or refractory peripheral T Cell lymphoma (PTCL) was evaluated.
  • Twenty-one adult patients with relapsed or refractory CD4(+) PTCL of non-cutaneous type (angioimmunoblastic T cell lymphoma (AITL) n = 9, PTCL-not otherwise specified (NOS) n = 7, anaplastic large cell lymphoma (ALCL) n = 4 and enteropathy type T cell lymphoma n = 1) were treated in a single-arm multi-centre study, with weekly intravenous infusions of zanolimumab 980 mg for 12 weeks.
  • Seventeen of the patients had advanced stage disease (Ann Arbor stages III-IV).
  • Responses were obtained in different PTCL entities: AITL (n = 3), ALCL (n = 1) and PTCL-NOS (n = 1).
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Antineoplastic Agents / therapeutic use. Lymphoma, T-Cell, Peripheral / drug therapy

  • Genetic Alliance. consumer health - Cutaneous T-Cell Lymphoma.
  • Genetic Alliance. consumer health - Peripheral T-cell lymphoma.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20629661.001).
  • [ISSN] 1365-2141
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antineoplastic Agents; 0 / zanolimumab
  •  go-up   go-down


87. Alizadeh AA, Advani RH: Evaluation and management of angioimmunoblastic T-cell lymphoma: a review of current approaches and future strategies. Clin Adv Hematol Oncol; 2008 Dec;6(12):899-909
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Evaluation and management of angioimmunoblastic T-cell lymphoma: a review of current approaches and future strategies.
  • Angioimmunoblastic T-cell lymphoma (AITL) is a rare and complex lymphoproliferative disorder, clinically characterized by widespread lymphadenopathy, extranodal disease, immune-mediated hemolysis, and polyclonal hypergammaglobulinemia.
  • Significant progress has been made in the understanding of AITL since its recognition as a clonal T-cell disorder with associated deregulation of B-cells and endothelial cells within a unique malignant microenvironment.
  • We discuss recent developments in the understanding of the pathogenesis of AITL at a cellular and molecular level, including the implication of the follicular helper T-cell as the corresponding cell of origin, the roles of Epstein-Barr virus, B-cell deregulation, angiogenesis, and other signaling pathways in AITL, and the therapeutic implications of these findings.
  • [MeSH-major] Immunoblastic Lymphadenopathy / diagnosis. Immunoblastic Lymphadenopathy / therapy. Lymphoma, T-Cell, Peripheral / diagnosis. Lymphoma, T-Cell, Peripheral / therapy

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. RITUXIMAB .
  • Hazardous Substances Data Bank. CYCLOSPORIN A .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19209140.001).
  • [ISSN] 1543-0790
  • [Journal-full-title] Clinical advances in hematology & oncology : H&O
  • [ISO-abbreviation] Clin Adv Hematol Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Angiogenesis Inhibitors; 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Antineoplastic Agents; 0 / Immunosuppressive Agents; 2S9ZZM9Q9V / Bevacizumab; 4F4X42SYQ6 / Rituximab; 83HN0GTJ6D / Cyclosporine
  • [Number-of-references] 100
  •  go-up   go-down


88. Matsui K, Adachi M, Tominaga T, Shinohara K, Kamei T: Angioimmunoblastic T cell lymphoma associated with reversible myelofibrosis. Intern Med; 2008;47(21):1921-4
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Angioimmunoblastic T cell lymphoma associated with reversible myelofibrosis.
  • Biopsy of the lymph node demonstrated angioimmunoblastic T cell lymphoma (AITL) with the loss of normal architecture, proliferation of neoplastic T cells, small vessels mixed with eosinophils and plasma cells.
  • After chemotherapy, remission of lymphoma was achieved.
  • [MeSH-major] Immunoblastic Lymphadenopathy / diagnosis. Primary Myelofibrosis / diagnosis
  • [MeSH-minor] Humans. Lymphoma, T-Cell / complications. Lymphoma, T-Cell / diagnosis. Lymphoma, T-Cell / drug therapy. Male. Middle Aged

  • Genetic Alliance. consumer health - Myelofibrosis.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18981638.001).
  • [ISSN] 1349-7235
  • [Journal-full-title] Internal medicine (Tokyo, Japan)
  • [ISO-abbreviation] Intern. Med.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


89. Went P, Agostinelli C, Gallamini A, Piccaluga PP, Ascani S, Sabattini E, Bacci F, Falini B, Motta T, Paulli M, Artusi T, Piccioli M, Zinzani PL, Pileri SA: Marker expression in peripheral T-cell lymphoma: a proposed clinical-pathologic prognostic score. J Clin Oncol; 2006 Jun 1;24(16):2472-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Marker expression in peripheral T-cell lymphoma: a proposed clinical-pathologic prognostic score.
  • PURPOSE: Although peripheral T-cell lymphoma, unspecified (PTCL/U), is the most common T-cell tumor in Western countries, no study to date has been based on the application of a wide panel of markers to a large series of patients and assessed the impact of phenotype on survival.
  • We evaluated the expression of 19 markers in 148 PTCLs/U and 45 PTCLs of the angioimmunoblastic type (AILD).
  • RESULTS: An aberrant phenotype with frequent loss of CD5 and/or CD7 was typical for PTCLs, irrespective of whether they were U or AILD.
  • The latter represents one of the first examples of mixed score (including patient- and tumor-specific factors) applied to malignant lymphomas and may be the basis for future prospective therapeutic trials.
  • [MeSH-major] Antigens, CD / analysis. Biomarkers, Tumor / analysis. Ki-67 Antigen / analysis. Lymphoma, T-Cell, Peripheral / chemistry. Lymphoma, T-Cell, Peripheral / pathology

  • Genetic Alliance. consumer health - Peripheral T-cell lymphoma.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16636342.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Antigens, CD15; 0 / Antigens, CD2; 0 / Antigens, CD20; 0 / Antigens, CD3; 0 / Antigens, CD30; 0 / Antigens, CD4; 0 / Antigens, CD5; 0 / Antigens, CD7; 0 / Antigens, CD8; 0 / Biomarkers, Tumor; 0 / Ki-67 Antigen; EC 3.4.24.11 / Neprilysin
  •  go-up   go-down


90. Marafioti T, Paterson JC, Ballabio E, Chott A, Natkunam Y, Rodriguez-Justo M, Plonquet A, Rodriguez-Pinilla SM, Klapper W, Hansmann ML, Pileri SA, Isaacson PG, Stein H, Piris MA, Mason DY, Gaulard P: The inducible T-cell co-stimulator molecule is expressed on subsets of T cells and is a new marker of lymphomas of T follicular helper cell-derivation. Haematologica; 2010 Mar;95(3):432-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The inducible T-cell co-stimulator molecule is expressed on subsets of T cells and is a new marker of lymphomas of T follicular helper cell-derivation.
  • BACKGROUND: T follicular helper (T(FH)) cells reside in the light zone of germinal centers and are considered the cell of origin of angioimmunoblastic T-cell lymphoma.
  • Recently, CXCL13, PD-1 and SAP were described as useful markers for T(FH) cells and angioimmunoblastic T-cell lymphoma but also reported in some peripheral T-cell lymphomas, not otherwise specified.
  • DESIGN AND METHODS: In the present study the expression pattern of ICOS protein was investigated by immunohistochemistry-based techniques in routine sections of normal lymphoid tissues and 633 human lymphomas.
  • In lymphomas, ICOS expression was confined to angioimmunoblastic T-cell lymphoma (85/86), peripheral T-cell lymphomas of follicular variant (18/18) and a proportion of peripheral T-cell lymphomas, not otherwise specified (24/56) that also expressed other T(FH)-associated molecules.
  • CONCLUSIONS: ICOS is a useful molecule for identifying T(FH) cells and its restricted expression to angioimmunoblastic T-cell lymphoma and a proportion of peripheral T-cell lymphomas, not otherwise specified (showing a T(FH)-like profile) suggests its inclusion in the antibody panel for diagnosing T(FH)-derived lymphomas.
  • Our findings provide further evidence that the histological spectrum of T(FH)-derived lymphomas is broader than previously assumed.
  • [MeSH-major] Antigens, Differentiation, T-Lymphocyte / metabolism. Biomarkers, Tumor / metabolism. Immunoblastic Lymphadenopathy / diagnosis. Lymphoma, Follicular / diagnosis. Lymphoma, T-Cell, Peripheral / diagnosis. T-Lymphocytes, Helper-Inducer / metabolism
  • [MeSH-minor] Cells, Cultured. Flow Cytometry. Humans. Immunophenotyping. Inducible T-Cell Co-Stimulator Protein. Prognosis

  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cytometry. 2000 Jun 15;42(3):180-7 [10861691.001]
  • [Cites] Mod Pathol. 2009 Jun;22(6):753-61 [19329936.001]
  • [Cites] J Immunol. 2000 Nov 1;165(9):5035-40 [11046032.001]
  • [Cites] Eur J Immunol. 2000 Dec;30(12):3707-17 [11169414.001]
  • [Cites] Am J Surg Pathol. 2001 Mar;25(3):395-400 [11224611.001]
  • [Cites] Nature. 2001 Jan 4;409(6816):97-101 [11343121.001]
  • [Cites] Nature. 2001 Jan 4;409(6816):102-5 [11343122.001]
  • [Cites] Nature. 2001 Jan 4;409(6816):105-9 [11343123.001]
  • [Cites] Nat Immunol. 2001 Jul;2(7):573-4 [11429535.001]
  • [Cites] Nat Immunol. 2001 Jul;2(7):597-604 [11429543.001]
  • [Cites] J Immunol. 2001 Nov 15;167(10):5741-8 [11698447.001]
  • [Cites] Blood. 2002 Jan 15;99(2):627-33 [11781247.001]
  • [Cites] Transplantation. 2002 Apr 15;73(7):1027-32 [11965027.001]
  • [Cites] Mod Pathol. 2002 Dec;15(12):1374-80 [12481020.001]
  • [Cites] J Exp Med. 2003 Jan 20;197(2):181-93 [12538658.001]
  • [Cites] J Immunol. 2003 Mar 1;170(5):2310-5 [12594252.001]
  • [Cites] Eur J Immunol. 2003 Feb;33(2):392-401 [12645936.001]
  • [Cites] Br J Haematol. 2003 Jun;121(5):681-91 [12780782.001]
  • [Cites] J Clin Invest. 2003 Jul;112(2):234-43 [12865411.001]
  • [Cites] Nat Rev Immunol. 2003 Jul;3(7):544-56 [12876557.001]
  • [Cites] Nat Immunol. 2003 Aug;4(8):765-72 [12833154.001]
  • [Cites] Blood. 2003 Aug 15;102(4):1381-8 [12714510.001]
  • [Cites] Curr Opin Immunol. 2004 Jun;16(3):321-7 [15134781.001]
  • [Cites] J Immunol. 2004 Jul 1;173(1):68-78 [15210760.001]
  • [Cites] Blood. 2004 Oct 1;104(7):1952-60 [15213097.001]
  • [Cites] Nature. 1999 Jan 21;397(6716):263-6 [9930702.001]
  • [Cites] Annu Rev Immunol. 2005;23:515-48 [15771580.001]
  • [Cites] Blood. 2005 Apr 15;105(8):3372-80 [15618467.001]
  • [Cites] Nature. 2005 May 26;435(7041):452-8 [15917799.001]
  • [Cites] Hum Pathol. 2005 Jul;36(7):784-91 [16084948.001]
  • [Cites] Cell Mol Immunol. 2004 Feb;1(1):37-42 [16212919.001]
  • [Cites] Leukemia. 2006 Feb;20(2):296-303 [16341050.001]
  • [Cites] Vaccine. 2006 Apr 5;24(15):3035-43 [16364514.001]
  • [Cites] Am J Surg Pathol. 2006 Apr;30(4):490-4 [16625095.001]
  • [Cites] Virchows Arch. 2006 Jul;449(1):78-87 [16633785.001]
  • [Cites] Am J Surg Pathol. 2006 Jul;30(7):802-10 [16819321.001]
  • [Cites] Mod Pathol. 2006 Aug;19(8):1101-7 [16680156.001]
  • [Cites] Blood. 2007 Jun 1;109(11):4952-63 [17284527.001]
  • [Cites] Haematologica. 2007 Aug;92(8):1059-66 [17640856.001]
  • [Cites] Nature. 2007 Nov 8;450(7167):299-303 [18172933.001]
  • [Cites] J Immunol. 2008 Jan 15;180(2):774-82 [18178815.001]
  • [Cites] Blood. 2008 Apr 1;111(7):3778-92 [18218851.001]
  • [Cites] Immunity. 2008 Jun;28(6):870-80 [18513999.001]
  • [Cites] Hum Pathol. 2008 Jul;39(7):1050-8 [18479731.001]
  • [Cites] J Clin Oncol. 2008 Sep 1;26(25):4124-30 [18626005.001]
  • [Cites] Br J Haematol. 2008 Nov;143(3):439-41 [18729855.001]
  • [Cites] Am J Surg Pathol. 2008 Dec;32(12):1787-99 [18779728.001]
  • [Cites] Science. 2009 Mar 13;323(5920):1488-92 [19286559.001]
  • [Cites] Am J Surg Pathol. 2009 May;33(5):682-90 [19295409.001]
  • [CommentIn] Haematologica. 2010 Mar;95(3):356-8 [20207841.001]
  • (PMID = 20207847.001).
  • [ISSN] 1592-8721
  • [Journal-full-title] Haematologica
  • [ISO-abbreviation] Haematologica
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Antigens, Differentiation, T-Lymphocyte; 0 / Biomarkers, Tumor; 0 / ICOS protein, human; 0 / Inducible T-Cell Co-Stimulator Protein
  • [Other-IDs] NLM/ PMC2833073
  •  go-up   go-down


91. Lee Y, Lee KW, Kim JH, Bang SM, Lee JS, Park BB, Kim WS, Suh C, Kang JH, Ryoo BY, Lee JH, Shin DB: Epstein-Barr virus-positivity in tumor has no correlation with the clinical outcomes of patients with angioimmunoblastic T-cell lymphoma. Korean J Intern Med; 2008 Mar;23(1):30-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Epstein-Barr virus-positivity in tumor has no correlation with the clinical outcomes of patients with angioimmunoblastic T-cell lymphoma.
  • BACKGROUND/AIMS: Epstein-Barr virus (EBV) is involved in the pathogenesis of angioimmunoblastic T-cell lymphoma (AILT), but its precise role and prognostic impact are not clear.
  • This study aimed to evaluate the incidence of EBV-postitivity in the tumor and bone marrow (BM) samples from AILT patients, and their correlations with the clinical variables and patient survival.
  • METHODS: Seventy AILT cases were identified over a period of 8 years.
  • In 13 (48%) patients, gross tumor involvement was recognized by hematoxylin-eosin staining at the time of diagnosis.
  • CONCLUSIONS: EBV-positivity of tumor had no impact on the prognosis of AILT patients.
  • [MeSH-major] Herpesvirus 4, Human / isolation & purification. Immunoblastic Lymphadenopathy / virology. Lymphoma, T-Cell / virology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Pathol. 2000 Feb;156(2):661-9 [10666395.001]
  • [Cites] Am J Clin Pathol. 2007 Jun;127(6):860-8 [17509983.001]
  • [Cites] Am J Clin Pathol. 2000 Aug;114(2):236-47 [10941339.001]
  • [Cites] Am J Clin Pathol. 2002 Mar;117(3):368-79 [11888076.001]
  • [Cites] Leuk Lymphoma. 2002 Apr;43(4):805-11 [12153168.001]
  • [Cites] Int J Cancer. 2003 Jan 1;103(1):12-20 [12455048.001]
  • [Cites] Lancet Infect Dis. 2003 Mar;3(3):131-40 [12614729.001]
  • [Cites] N Engl J Med. 2004 Mar 25;350(13):1328-37 [15044644.001]
  • [Cites] J Korean Med Sci. 2004 Apr;19(2):229-33 [15082896.001]
  • [Cites] Ann Oncol. 2004 Oct;15(10):1467-75 [15367405.001]
  • [Cites] Int J Cancer. 1976 Feb 15;17(2):177-81 [175027.001]
  • [Cites] Blood. 1991 Feb 15;77(4):799-808 [1847084.001]
  • [Cites] Blood. 1992 Apr 1;79(7):1789-95 [1373088.001]
  • [Cites] Blood. 1992 Jul 15;80(2):484-91 [1320954.001]
  • [Cites] Blood. 1992 Oct 1;80(7):1804-12 [1327284.001]
  • [Cites] Histopathology. 1993 Feb;22(2):145-9 [8384155.001]
  • [Cites] Ann Oncol. 1995 Sep;6(7):659-64 [8664186.001]
  • [Cites] Haematologica. 2005 Aug;90(8):1063-9 [16079105.001]
  • [Cites] Haematologica. 2005 Sep;90(9):1192-6 [16154842.001]
  • [Cites] Hematology Am Soc Hematol Educ Program. 2005;:260-6 [16304390.001]
  • [Cites] J Mol Diagn. 2006 Sep;8(4):466-75; quiz 527 [16931587.001]
  • [Cites] Leuk Lymphoma. 2007 Apr;48(4):716-22 [17454629.001]
  • [Cites] N Engl J Med. 2000 Aug 17;343(7):481-92 [10944566.001]
  • (PMID = 18363277.001).
  • [ISSN] 1226-3303
  • [Journal-full-title] The Korean journal of internal medicine
  • [ISO-abbreviation] Korean J. Intern. Med.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Korea (South)
  • [Chemical-registry-number] 0 / DNA, Viral
  • [Other-IDs] NLM/ PMC2686953
  •  go-up   go-down


92. Saitoh T, Matsushima T, Matsuo A, Yokohama A, Irisawa H, Handa H, Tsukamoto N, Karasawa M, Nojima Y, Murakami H: Small-bowel perforation accompanied by Aspergillus endocarditis in a patient with angioimmunoblastic T-cell lymphoma. Ann Hematol; 2007 Jan;86(1):71-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Small-bowel perforation accompanied by Aspergillus endocarditis in a patient with angioimmunoblastic T-cell lymphoma.
  • [MeSH-major] Aspergillosis / complications. Aspergillus fumigatus. Endocarditis / microbiology. Immunoblastic Lymphadenopathy / complications. Intestinal Perforation / complications. Intestine, Small. Lymphoma, T-Cell / complications

  • Genetic Alliance. consumer health - Endocarditis.
  • MedlinePlus Health Information. consumer health - Aspergillosis.
  • MedlinePlus Health Information. consumer health - Endocarditis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17043778.001).
  • [ISSN] 1432-0584
  • [Journal-full-title] Annals of hematology
  • [ISO-abbreviation] Ann. Hematol.
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] Germany
  •  go-up   go-down


93. Advani R, Horwitz S, Zelenetz A, Horning SJ: Angioimmunoblastic T cell lymphoma: treatment experience with cyclosporine. Leuk Lymphoma; 2007 Mar;48(3):521-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Angioimmunoblastic T cell lymphoma: treatment experience with cyclosporine.
  • Angioimmunoblastic T cell lymphoma is a distinct entity for which there is no standard therapy.
  • On the basis of the rationale that CsA may represent a novel drug for AITL, a disease with considerable immune dysregulation, and encouraging case reports, the authors have treated 12 patients with this agent.
  • By interrupting T-cell activation, CsA may alter the immune dysregulation that characterizes AILT.
  • The efficacy of CsA is being explored in patients with recurrent AILT in a prospective trial (ECOG 2402).
  • [MeSH-major] Cyclosporine / therapeutic use. Immunoblastic Lymphadenopathy / drug therapy. Immunosuppressive Agents / therapeutic use. Lymphoma, T-Cell, Peripheral / drug therapy

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CYCLOSPORIN A .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Leuk Lymphoma. 2007 Mar;48(3):449-51 [17454581.001]
  • (PMID = 17454592.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Immunosuppressive Agents; 83HN0GTJ6D / Cyclosporine
  •  go-up   go-down


94. Mitarnun W, Suwiwat S, Pradutkanchana J: Epstein-Barr virus-associated extranodal non-Hodgkin's lymphoma of the sinonasal tract and nasopharynx in Thailand. Asian Pac J Cancer Prev; 2006 Jan-Mar;7(1):91-4
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Epstein-Barr virus-associated extranodal non-Hodgkin's lymphoma of the sinonasal tract and nasopharynx in Thailand.
  • Epstein-Barr virus (EBV) infection is highly associated with specific subtypes of malignant lymphoma.
  • In our previous report on nodal malignant lymphoma in Thailand, we found that 64% of classical Hodgkin's lymphoma (cHL), 51% of non-Hodgkin's lymphoma, T-cell (NHL-T), and 13% of non-Hodgkin's lymphoma, B-cell (NHL-B) were EBV-related.
  • In the present research, we conducted a retrospective study of primary extranodal non-Hodgkin's lymphoma of the sinonasal tract (e-NHL-ST) and primary extranodal non-Hodgkin's lymphoma of the nasopharynx (e-NHL-NP) in Southern Thailand, between 1997 and 2004.
  • EBV-encoded RNA (EBER) expression by in situ hybridization was performed in all cases and a T-cell receptor (TCR)-g gene rearrangement study was performed in NHL-T cases.
  • The percentages of e-NHL-ST and e-NHL-NP as compared to nodal malignant lymphoma were 3.7% and 6.8%, respectively.
  • Monoclonal bands of the TCR-gamma gene were detected in 71.4% of the extranodal NK/T-cell lymphomas, nasal type, patients; 50.0% of peripheral T-cell lymphoma, unspecified, patients; and one case of angioimmunoblastic T-cell lymphoma.
  • The study also indicates that most cases of extranodal NK/T-cell lymphoma, nasal type, are not the germline configuration of the TCR genes.
  • [MeSH-major] Herpesvirus 4, Human / isolation & purification. Lymphoma, Non-Hodgkin / epidemiology. Lymphoma, Non-Hodgkin / virology. Nasopharyngeal Neoplasms / virology. Paranasal Sinus Neoplasms / virology
  • [MeSH-minor] Adult. Age Distribution. Aged. Aged, 80 and over. Cohort Studies. DNA, Viral / analysis. Female. Humans. In Situ Hybridization. Incidence. Lymph Nodes / pathology. Lymphoma, T-Cell / epidemiology. Lymphoma, T-Cell / pathology. Lymphoma, T-Cell / virology. Male. Middle Aged. Polymerase Chain Reaction. Prognosis. Retrospective Studies. Risk Assessment. Sex Distribution. Survival Rate. Thailand / epidemiology

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16629523.001).
  • [ISSN] 1513-7368
  • [Journal-full-title] Asian Pacific journal of cancer prevention : APJCP
  • [ISO-abbreviation] Asian Pac. J. Cancer Prev.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Thailand
  • [Chemical-registry-number] 0 / DNA, Viral
  •  go-up   go-down


95. Jones B, Vun Y, Sabah M, Egan CA: Toxic epidermal necrolysis secondary to angioimmunoblastic T-cell lymphoma. Australas J Dermatol; 2005 Aug;46(3):187-91
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Toxic epidermal necrolysis secondary to angioimmunoblastic T-cell lymphoma.
  • A 67-year-old man presented with a history of lymphadenopathy, fevers and separate skin eruptions of erythrodermic spongiotic dermatitis initially and subsequent toxic epidermal necrolysis.
  • Initial lymph node biopsies showed non-specific granulomatous changes, and skin biopsies and bone marrow aspirate were not diagnostic.
  • Due to persisting lymphadenopathy, further lymph node biopsy led to the diagnosis of angioimmunoblastic T-cell lymphoma, a rare form of peripheral T-cell lymphoma with a poor prognosis.
  • At the time of diagnosis his condition deteriorated rapidly and he died soon after.
  • [MeSH-major] Head and Neck Neoplasms / complications. Immunoblastic Lymphadenopathy / complications. Lymphoma, T-Cell / complications. Stevens-Johnson Syndrome / etiology

  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16008654.001).
  • [ISSN] 0004-8380
  • [Journal-full-title] The Australasian journal of dermatology
  • [ISO-abbreviation] Australas. J. Dermatol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / Immunoglobulins, Intravenous
  •  go-up   go-down


96. Iannitto E, Ferreri AJ, Minardi V, Tripodo C, Kreipe HH: Angioimmunoblastic T-cell lymphoma. Crit Rev Oncol Hematol; 2008 Dec;68(3):264-71
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Angioimmunoblastic T-cell lymphoma.
  • Angioimmunoblastic T-cell lymphoma (AITL) is a rare and aggressive neoplasm clinically characterized by sudden onset of constitutional symptoms, lymphadenopathy, hepatosplenomegaly, frequent autoimmune phenomena, particularly hemolytic anemia and thrombocytopenia, and polyclonal hypergammaglobulinemia.
  • The neoplastic CD4+ T-cells represent a minority of the lymph node cell population; its detection is facilitated by the aberrant expression of CD10.
  • Almost all cases arbor an EBV infected B-cell population.
  • Patients achieving a good clinical response seem beneficiate from a consolidation with high-dose therapy and autologous stem cell transplantation.
  • [MeSH-major] Immunosuppressive Agents / therapeutic use. Lymphoma, T-Cell / drug therapy. Stem Cell Transplantation. Thalidomide / therapeutic use
  • [MeSH-minor] B-Lymphocytes / metabolism. B-Lymphocytes / pathology. B-Lymphocytes / virology. CD4-Positive T-Lymphocytes / metabolism. CD4-Positive T-Lymphocytes / pathology. Cell Proliferation. Dendritic Cells / metabolism. Dendritic Cells / pathology. Epstein-Barr Virus Infections / metabolism. Epstein-Barr Virus Infections / mortality. Epstein-Barr Virus Infections / pathology. Epstein-Barr Virus Infections / therapy. Female. Herpesvirus 4, Human. Humans. Lymph Nodes / metabolism. Lymph Nodes / pathology. Male. Neprilysin / metabolism. Survival Rate. Transplantation, Autologous

  • Hazardous Substances Data Bank. THALIDOMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18684638.001).
  • [ISSN] 1040-8428
  • [Journal-full-title] Critical reviews in oncology/hematology
  • [ISO-abbreviation] Crit. Rev. Oncol. Hematol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Immunosuppressive Agents; 4Z8R6ORS6L / Thalidomide; EC 3.4.24.11 / Neprilysin
  • [Number-of-references] 57
  •  go-up   go-down


97. Kyriakou C, Canals C, Finke J, Kobbe G, Harousseau JL, Kolb HJ, Novitzky N, Goldstone AH, Sureda A, Schmitz N: Allogeneic stem cell transplantation is able to induce long-term remissions in angioimmunoblastic T-cell lymphoma: a retrospective study from the lymphoma working party of the European group for blood and marrow transplantation. J Clin Oncol; 2009 Aug 20;27(24):3951-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Allogeneic stem cell transplantation is able to induce long-term remissions in angioimmunoblastic T-cell lymphoma: a retrospective study from the lymphoma working party of the European group for blood and marrow transplantation.
  • PURPOSE: To analyze the long-term outcome in terms of nonrelapse mortality (NRM), relapse rate (RR), progression-free survival (PFS), and overall survival (OS) in patients with angioimmunoblastic T-cell lymphoma (AITL) treated with allogeneic stem-cell transplantation (alloSCT).
  • Median age was 48 years (range, 23 to 68 years), 34 patients had received > or = two lines of chemotherapy before alloSCT, and 11 patients had experienced treatment failure with a prior autologous stem-cell transplantation.
  • Twenty-seven patients were allografted in chemotherapy-sensitive disease, and 18 were allografted in refractory disease.
  • RR was estimated as 16% and 20% at 2 and 3 years, respectively, and was lower in patients developing chronic graft-versus-host disease (cGVHD).
  • Both the lower RR after transplantation as well as the decreased RR in patients developing cGVHD after the alloSCT suggests the existence of a clinically relevant graft-versus-lymphoma effect.
  • [MeSH-major] Hematopoietic Stem Cell Transplantation. Lymphoma, T-Cell, Peripheral / therapy
  • [MeSH-minor] Adult. Aged. Female. Graft vs Host Disease / epidemiology. Humans. Male. Middle Aged. Recurrence. Retrospective Studies. Transplantation, Homologous

  • Genetic Alliance. consumer health - Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19620487.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


98. Ballester B, Ramuz O, Gisselbrecht C, Doucet G, Loï L, Loriod B, Bertucci F, Bouabdallah R, Devilard E, Carbuccia N, Mozziconacci MJ, Birnbaum D, Brousset P, Berger F, Salles G, Briére J, Houlgatte R, Gaulard P, Xerri L: Gene expression profiling identifies molecular subgroups among nodal peripheral T-cell lymphomas. Oncogene; 2006 Mar 9;25(10):1560-70
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gene expression profiling identifies molecular subgroups among nodal peripheral T-cell lymphomas.
  • The classification of peripheral T-cell lymphomas (PTCL) is still a matter of debate.
  • To establish a molecular classification of PTCL, we analysed 59 primary nodal T-cell lymphomas using cDNA microarrays, including 56 PTCL and three T-lymphoblastic lymphoma (T-LBL).
  • The expression profiles could discriminate angioimmunoblastic lymphoma, anaplastic large-cell lymphoma and T-LBL.
  • The U2 subgroup was associated with overexpression of genes involved in T-cell activation and apoptosis, including NFKB1 and BCL-2.
  • [MeSH-major] Gene Expression Profiling. Lymph Nodes / pathology. Lymphoma, T-Cell / genetics. Lymphoma, T-Cell / pathology

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16288225.001).
  • [ISSN] 0950-9232
  • [Journal-full-title] Oncogene
  • [ISO-abbreviation] Oncogene
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


99. Tan BT, Seo K, Warnke RA, Arber DA: The frequency of immunoglobulin heavy chain gene and T-cell receptor gamma-chain gene rearrangements and Epstein-Barr virus in ALK+ and ALK- anaplastic large cell lymphoma and other peripheral T-cell lymphomas. J Mol Diagn; 2008 Nov;10(6):502-12
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The frequency of immunoglobulin heavy chain gene and T-cell receptor gamma-chain gene rearrangements and Epstein-Barr virus in ALK+ and ALK- anaplastic large cell lymphoma and other peripheral T-cell lymphomas.
  • We previously identified a relatively high frequency of B-cell proliferations along with simultaneous T-cell receptor gamma-chain gene (TRG) and immunoglobulin heavy chain gene (IGH) rearrangements in a series of angioimmunoblastic T-cell lymphoma and peripheral T-cell lymphoma, unspecified.
  • Here, we report on a series of 74 peripheral T-cell lymphoma (PTCL) cases composed entirely of specific PTCL subtypes, including 28 cases of ALK+ anaplastic large-cell lymphoma (ALCL), 35 cases of ALK- ALCL, and 11 cases that represent other specific PTCL subtypes.
  • We performed IGH and TRG gene rearrangement studies and in situ hybridization for Epstein-Barr virus (EBV) to determine the frequency of IGH clonality and to investigate the relationship between EBV, clonality, and associated B-cell proliferations.
  • Despite the detection of occasional IGH clones, there was no correlation between IGH clonality and EBV, and B-cell proliferations were not identified in any of the cases.
  • These findings suggest that other factors contribute to IGH clonality and demonstrate that, in the absence of an associated B-cell proliferation, IGH clonality occurs infrequently (8%) in specific PTCL subtypes.
  • [MeSH-major] Gene Rearrangement. Genes, T-Cell Receptor gamma. Herpesvirus 4, Human / immunology. Immunoglobulin Heavy Chains / genetics. Lymphoma, Large-Cell, Anaplastic / genetics. Lymphoma, T-Cell, Peripheral / genetics. Protein-Tyrosine Kinases / metabolism. Receptors, Antigen, T-Cell, gamma-delta / genetics

  • Genetic Alliance. consumer health - Anaplastic Large Cell Lymphoma.
  • Genetic Alliance. consumer health - Lymphoma, large-cell.
  • Genetic Alliance. consumer health - Peripheral T-cell lymphoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Clin Pathol. 2000 Aug;114(2):236-47 [10941339.001]
  • [Cites] Br J Haematol. 2007 Jul;138(1):31-43 [17555445.001]
  • [Cites] Blood. 2000 Sep 15;96(6):2254-61 [10979974.001]
  • [Cites] Mol Pathol. 2000 Aug;53(4):194-200 [11040942.001]
  • [Cites] Mod Pathol. 2000 Dec;13(12):1269-79 [11144922.001]
  • [Cites] J Mol Diagn. 2000 May;2(2):92-6 [11272894.001]
  • [Cites] Diagn Mol Pathol. 2001 Jun;10(2):69-77 [11385314.001]
  • [Cites] J Mol Diagn. 2001 Nov;3(4):133-40 [11687596.001]
  • [Cites] Am J Clin Pathol. 2002 Mar;117(3):368-79 [11888076.001]
  • [Cites] Blood. 2002 Apr 1;99(7):2315-23 [11895762.001]
  • [Cites] J Pathol. 2002 Oct;198(2):171-80 [12237876.001]
  • [Cites] Leukemia. 2002 Oct;16(10):2134-41 [12357368.001]
  • [Cites] Am J Clin Pathol. 2002 Dec;118(6):848-54 [12472277.001]
  • [Cites] Lancet. 2003 Jan 18;361(9353):217-23 [12547545.001]
  • [Cites] J Mol Diagn. 2003 May;5(2):82-7 [12707372.001]
  • [Cites] Eur J Immunol. 2003 Jun;33(6):1593-602 [12778477.001]
  • [Cites] Leuk Lymphoma. 2003 May;44(5):807-13 [12802918.001]
  • [Cites] Leukemia. 2003 Sep;17(9):1834-44 [12970784.001]
  • [Cites] Blood. 2003 Nov 15;102(10):3775-85 [12907442.001]
  • [Cites] Leukemia. 2003 Dec;17(12):2257-317 [14671650.001]
  • [Cites] Blood. 1983 Jun;61(6):1138-45 [6404327.001]
  • [Cites] EMBO J. 1984 Jun;3(6):1209-19 [6086308.001]
  • [Cites] Blood. 1986 Jan;67(1):1-11 [3079640.001]
  • [Cites] Am J Clin Pathol. 1986 Apr;85(4):490-3 [2420169.001]
  • [Cites] Leukemia. 1987 Mar;1(3):235 [3669744.001]
  • [Cites] Clin Chim Acta. 1991 Apr;198(1-2):93-174 [1863986.001]
  • [Cites] J Clin Pathol. 1995 Nov;48(11):1045-50 [8543629.001]
  • [Cites] J Exp Med. 1996 Oct 1;184(4):1495-505 [8879220.001]
  • [Cites] Leukemia. 1998 Jul;12(7):1081-8 [9665194.001]
  • [Cites] Leukemia. 1999 Feb;13(2):196-205 [10025893.001]
  • [Cites] Mol Diagn. 1999 Jun;4(2):119-33 [10462627.001]
  • [Cites] Mol Pathol. 1999 Apr;52(2):104-10 [10474690.001]
  • [Cites] J Mol Diagn. 2005 Oct;7(4):495-503 [16237219.001]
  • [Cites] Br J Dermatol. 2006 Jan;154(1):162-6 [16403112.001]
  • [Cites] J Mol Diagn. 2006 Sep;8(4):466-75; quiz 527 [16931587.001]
  • [Cites] Leukemia. 2007 Feb;21(2):215-21 [17170730.001]
  • [Cites] Leukemia. 2007 Feb;21(2):207-14 [17170731.001]
  • [Cites] Diagn Mol Pathol. 2000 Sep;9(3):132-6 [10976719.001]
  • (PMID = 18832464.001).
  • [ISSN] 1525-1578
  • [Journal-full-title] The Journal of molecular diagnostics : JMD
  • [ISO-abbreviation] J Mol Diagn
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Immunoglobulin Heavy Chains; 0 / Receptors, Antigen, T-Cell, gamma-delta; EC 2.7.10.1 / Protein-Tyrosine Kinases; EC 2.7.10.1 / Receptor Protein-Tyrosine Kinases; EC 2.7.10.1 / anaplastic lymphoma kinase
  • [Other-IDs] NLM/ PMC2570633
  •  go-up   go-down


100. Saito A, Miyazawa Y, Isoda A, Hatsumi N, Matsumoto M, Kojima M, Sawamura M: [Clinicopathological analysis of patients with angioimmunoblastic T-cell lymphoma (AILT)]. Rinsho Ketsueki; 2008 Feb;49(2):82-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinicopathological analysis of patients with angioimmunoblastic T-cell lymphoma (AILT)].
  • We retrospectively analyzed the clinical course and prognosis of 11 patients with angioimmunoblastic T-cell Lymphoma (AILT).
  • The disease can be classified into three categories based on histological findings: 3 cases of AILT with hyperplastic germinal centers, 4 cases of typical AILT, and 4 cases of AILT with numerous clear cells.
  • As the initial therapy, 10 patients received combination chemotherapy and only 1 patient received autologous peripheral blood stem cell transplantation.
  • Patients with AILT demonstrating hyperplastic germinal centers and no bone marrow infiltration were able to achieve long-term survival.
  • The survival time of AILT demonstrated a wide range.
  • [MeSH-major] Immunoblastic Lymphadenopathy / therapy. Lymphoma, T-Cell / therapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Female. Humans. Male. Middle Aged. Peripheral Blood Stem Cell Transplantation. Prognosis. Survival Rate

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18341037.001).
  • [ISSN] 0485-1439
  • [Journal-full-title] [Rinshō ketsueki] The Japanese journal of clinical hematology
  • [ISO-abbreviation] Rinsho Ketsueki
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down






Advertisement